Publication AWA
At the Public Information Bulletin of the Agency for Health Technology Assessment and Tariff System (AWA) has published reviews analyses for the evaluation of reimbursement applications:
- Skyrizi (risankizumab) for the treatment of patients with ulcerative colitis (UC)
- Skyrizi (risankizumab) for the treatment of patients with Crohn’s disease
We encourage you to read the full documents and submit comments within the prescribed period of 7 days from the date of publication.
